
Pharmaceuticals giant Bayer has announced an agreement with biotech company Lion Bioscience to develop genomics and chemical software.
By Pia Heikkila
Published: 16 October 2000 17:29 BST
The agreement will focus on growing pharmacophore infomatics - a technology that uses computer models to identify parts of chemical and biological structures involved in disease.
The agreement sees Lion Bioscience developing tools and IT systems for Bayer's platforms. The contract is worth $25m.
You will be heavily involved in the development of state-of-the art valuation and risk models for contingent option structures, along with their ...
C++ -Direct experience in stoch/local vol, Libor market model + other relevant FX / interest rate models -FO experience -Understanding of FX ...
The team is heavily involved in the development of state-of-the-art valuation and risk models for contingent option structures, along with their ...
CIO50 2008
The silicon.com CIO50 2008 profiles the most influential and innovative tech chiefs in the UK across all industries and organisation size, from the biggest FTSE100 companies to high growth dot-com start ups and the public sector. The list was voted on by the UK CIO community and a panel of experts. Find out more in our latest special report.
July 10th: Just MASH Marketing: The Customer Reference Mashup
TechNet Webcast: How Microsoft Does IT: Management and Operations in Windows Server...
Mashing it up with Support: Automate, Coordinate and Collaborate with the Incident...
Ensure Virtualization is Meeting Your Needs--Read this New White Paper
Stories from the web...
Copyright ©1995-2008 CNET Networks, Inc. All rights reserved. Top of page
Peter Cochrane Peter Cochrane's Blog: Quality by design Why do picky people settle for poor design at work?
Naked CIO The Naked CIO: Service level disagreements SLAs - not worth the paper they're written on?